Foliglurax

Foliglurax

Clinical data
Other names	DT2331; PXT-002331; PXT-2331
Identifiers
IUPAC name 4-[3-[4-nitroso-2-(5H-thieno[3,2-c]pyridin-6-ylidene)chromen-6-yl]propyl]morpholine
CAS Number	1883329-53-0 1883329-51-8 (dihydrochloride)
PubChem CID	135565465
ChemSpider	59718537
Chemical and physical data
Formula	C23H23N3O3S
Molar mass	421.52 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1COCCN1CCCC2=CC3=C(C=C2)OC(=C4C=C5C(=CN4)C=CS5)C=C3N=O
InChI InChI=1S/C23H23N3O3S/c27-25-19-13-22(20-14-23-17(15-24-20)5-11-30-23)29-21-4-3-16(12-18(19)21)2-1-6-26-7-9-28-10-8-26/h3-5,11-15,24H,1-2,6-10H2 Key:XHRLGFLGWZIPEE-UHFFFAOYSA-N

Foliglurax (developmental code names PXT-002331, DT2331) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR₄), which is under development by Prexton Therapeutics for the treatment of Parkinson's disease. It reached phase II clinical trials, but while it was found to be safe and showed some signs of clinical improvement, it failed to sufficiently distinguish itself from placebo to meet the study endpoints.

The other tautomeric form of foliglurax.